MAPT and supranuclear palsy, progressive, 1: Our primary pathology of interest in the context of PSP and CBD is 4R-tau, but other tauopathies such as latent Alzheimer pathology in older adults and non-tau molecular pathologies may also contribute to 18F-AV-1451 binding.